Article
Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis.
Oncology reports - 1 Nov 2012
Hu Chengjin, Liu Xiaolei, Chen Yingjian, Sun Xiaoming, Gong Yanwen, Geng Ming, Bi Liquan
Abstract excerpt
Biological therapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have noted promising outcomes for patients with non-small cell lung carcinoma (NSCLC), especially those with mutated EGFR. Tissue EGFR gene mutation testing can predict the benefit of taking a first-line EGFR-TKI, thus, allowing the physician to prescribe the most...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
